Studies revealed that cancer cells could secret EGF to activate the EGFR signaling pathway and suppress antitumor immunity.47,48 After PD-1-targeted therapies, a high level of CTLA-4 was expressed in the peripheral blood to regulate T-cell activity.49,50. The gene discussed is PDCD1; the disease is cancer.